GCM
RGNX icon

Graham Capital Management’s Regenxbio RGNX Stock Holding History

Graham Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,339
Closed -$103K – 1459
2026
Q1 		$103K Sell
12,339
-10,293
-45% -$108K ﹤0.01% 1038
2025
Q4 		$326K Sell
22,632
-6,676
-23% -$83.2K 0.01% 824
2025
Q3 		$283K Sell
29,308
-30,827
-51% -$273K ﹤0.01% 888
2025
Q2 		$494K Buy
60,135
+8,118
+16% +$68K 0.01% 833
2025
Q1 		$372K Buy
52,017
+23,475
+82% +$175K 0.01% 917
2024
Q4 		$221K Buy
28,542
+10,677
+60% +$100K ﹤0.01% 1049
2024
Q3 		$187K Buy
17,865
+5,490
+44% +$66.9K ﹤0.01% 929
2024
Q2 		$145K Buy
+12,375
New +$193K ﹤0.01% 901

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Graham Capital Management's RGNX Position: Q2 2026 in Review

Graham Capital Management sold out of Regenxbio (RGNX) in Q2 2026, closing a stake of 12,339 shares — an estimated $103K sold.

Graham Capital Management first reported a position in RGNX in Q2 2024 and held it in 8 quarters. The position peaked at $494K in Q2 2025. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Graham Capital Management reported no remaining Regenxbio position as of Q2 2026 after selling out during the quarter.
  • Graham Capital Management sold 12,339 Regenxbio shares in Q2 2026, an estimated $103K.
  • Graham Capital Management first reported a position in Regenxbio in Q2 2024 and held it in 8 quarters.
  • Graham Capital Management's Regenxbio position peaked at $494K in Q2 2025.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.